



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)



(51) International Patent Classification 6 :  A61K 31/495		A1	(11) International Publication Number: WO 97/01339
(43) International Publication Date: 16 January 1997 (16.01.97)			

(21) International Application Number: PCT/US96/10468	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 17 June 1996 (17.06.96)	
(30) Priority Data: 08/496,262 28 June 1995 (28.06.95) US	
(71) Applicant: ALLERGAN [US/US]; 8301 Mars Drive, Waco, TX 76712 (US).	
(72) Inventors: WHEELER, Larry, A.; 18 Valley View, Irvine, CA 92715 (US). WOLDEMUSSE, Elizabeth; 40 Gullwing, Laguna Niguel, CA 92677 (US). LAI, Ronald, K.; 3405 S. Plaza Drive, Santa Ana, CA 92704 (US).	Published <i>With international search report.</i>
(74) Agents: BARAN, Robert, J. et al.; Allergan, Inc., 2525 Dupont Drive, T-2 2-E, P.O. Box 19534, Irvine, CA 92713-9534 (US).	

(54) Title: METHOD OF USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES IN TREATING OCULAR NEURAL INJURY

## (57) Abstract

A method according to which neuroprotection is conferred upon ocular nerve cells by administration of a drug of formula (I) to the optic nerve and/or retina of a mammal within a period prior to or following an insult to ocular nerve cells but prior to cell death, wherein the 2-imidazolin-2-ylamino group may be in either the 5- or 6-position of the quinoxaline nucleus; x, y and z may be in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy is disclosed.



BEST AVAILABLE COPY

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**METHOD OF USING (2-IMIDAZOLIN-2-YLAMINO)  
QUINOXALINES IN TREATING OCULAR NEURAL INJURY**

Background of the Invention

5

The present invention relates to methods for the protection of the optic nerve and the retina of mammalian eyes from noxious provocations including damage by compressive (mechanical) effects of elevated intraocular pressure caused by glaucoma or other 10 etiologic factors and impaired blood flow to these nerves.

Glucoma is a disease of the eye characterized by increased intraocular pressure. On the basis of its etiology, glaucoma has been classified as primary or secondary. Further, primary glaucoma in 15 adults may be either chronic open-angle or chronic angle-closure. Secondary glaucoma results from pre-existing ocular diseases such as uveitis, intraocular tumor or enlarged cataract.


The underlying causes of primary glaucoma are not yet well known. 20 Increase intraocular pressure is due to obstruction or aqueous humor outflow. In chronic open-angle glaucoma, the anterior chamber and its anatomic structures appear normal, but drainage of the aqueous humor is impeded. In acute and chronic angle-closure glaucoma, the anterior chamber is shallow, the filtration angle is narrowed and the 25 iris may obstruct the trabecular meshwork at the entrance to the canal of Schlemm. Dilation of the pupil may push the root of the iris forward against the angle or may produce pupillary block and thus precipitate an acute attack of elevated intraocular pressure. Eyes with narrow anterior chamber angles are predisposed to acute angle-closure glaucoma attacks of varying degrees of severity. 30

Secondary glaucoma is caused by any interference with the flow of aqueous humor from the posterior chamber into the anterior chamber and, subsequently, into the canal of Schlemm. 35 Inflammatory disease of the anterior segment may prevent aqueous escape by causing complete posterior synechia in iris bombe, and may plug the drainage channel with exudates. Other common causes are

intraocular tumors, enlarged cataracts, ventral retinal vein occlusion, trauma to the eye, operative procedures and intraocular hemorrhage.

Considering all types together, glaucoma occurs in about 2% of all  
 5 persons over the age of 40 and may be asymptomatic for years before progressing to rapid loss of vision. In cases where surgery is not indicated, topical beta-adrenoceptor antagonists have been the drugs of choice for treating glaucoma. However, alpha adrenergic agonists are awaiting approval for use in the treatment of elevated intraocular  
 10 pressure and will probably become mainstays in the treatment of this disease once they become available.

Various quinoxaline derivatives having alpha<sub>2</sub> agonist activity have been suggested as therapeutic agents by, for example, Danielewicz, et  
 15 al. in U.S. Patent No.s 3,890,319 and 4,029,792. They disclose compounds as regulators of the cardiovascular system which have the following formula:




20

where the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-position of the quinoxaline nucleus; x, y and z may be in any of the remaining 5-, 6-, 7- or 8-positions and may be selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and  
 25 R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy. The presently useful compounds may be prepared in accordance with the procedures outlined by Danielewicz, et al. The contents of both U.S. Patent No.s 3,890,319 and 4,029,792 are hereby  
 30 incorporated by reference in their entirety.

In "Ocular Effects of a Relatively Selective Alpha-2 Agonist (UK-14,304-18) in Cats, Rabbits and Monkeys" [J.A. Burke, et al., Current Eye Rsrch., 5, (9), pp. 665-676 (1986)] the quinoxaline derivative was

-3-

shown to be effective in reducing intraocular pressure in rabbits, cats and monkeys. Compounds in this study were administered topically to the eye of the study animals.



5

It has long been known that one of the sequelae of glaucoma is damage to the optic nerve head. This damage, referred to as "cupping", results in depressions in areas of the nerve fiber of the optic disk. Loss of sight from this cupping is progressive and can lead to 10 blindness if the condition is not treated effectively.

Unfortunately lowering intraocular pressure by administration of drugs or by surgery to facilitate outflow of the aqueous humor is not always effective in obviating damage to the nerves in glaucomatous 15 conditions. This apparent contradiction is addressed by Cioffi and Van Buskirk [Surv. of Ophthalmol., 38, Suppl. p. S107-16, discussion S116-17, May 1994] in the article, "Microvasculature of the Anterior Optic Nerve". The abstract states:

20 The traditional definition of glaucoma as a disorder of increased intraocular pressure (IOP) oversimplifies the clinical situation. Some glaucoma patients never have higher than normal IOP and others continue to develop optic nerve damage despite maximal lowering of IOP.

25 Another possible factor in the etiology of glaucoma may be regulation of the regional microvasculature of the anterior optic nerve. One reason to believe that microvascular factors are important is that many microvascular diseases are associated with glaucomatous optic neuropathy.

30 Subsequent to Cioffi, et al., Matusi published a paper on the "Ophthalmologic aspects of Systemic Vasculitis" [Nippon Rinsho, 52 (8), p. 2158-63, August 1994] and added further support to the

assertion that many microvascular diseases are associated with glaucomatous optic neuropathy. The summary states:

Ocular findings of systemic vasculitis, such as polyarteritis nodosa, giant cell arteritis and aortitis syndrome were reviewed. Systemic lupus erythematosus is not categorized as systemic vasculitis, however its ocular findings are microangiopathic. Therefore, review of its ocular findings was included in this paper. The most common fundus finding in these diseases is ischemic optic neuropathy or retinal vascular occlusions. Therefore several points in diagnosis or pathogenesis of optic neuropathy and retinal and choroidal vaso-occlusion were discussed. Choroidal ischemia has come to be able to be diagnosed clinically, since fluorescein angiography was applied in these lesions. When choroidal arteries are occluded, overlying retinal pigment epithelium is damaged. This causes disruption of barrier function of the epithelium and allows fluid from choroidal vasculatures to pass into subsensory retinal spaces. This is a pathogenesis of serous detachment of the retina. The retinal arterial occlusion formed non-perfused retina. Such hypoxic retina released angiogenesis factors which stimulate retinal and iris neovascularizations and iris neovascularizations may cause neovascular glaucoma.

B. Schwartz, in "Circulatory Defects of the Optic Disk and Retina in Ocular Hypertension and High Pressure Open-Angle Glaucoma" [Surv. Ophthalmol., 38, Suppl. pp. S23-24, May 1994] discusses the measurement of progressive defects in the optic nerve and retina associated with the progression of glaucoma. He states:

Fluorescein defects are significantly correlated with visual field loss and retinal nerve fiber layer loss. The second circulatory defect is a decrease of flow of fluorescein in the retinal vessels, especially the retinal veins, so that the greater the age, diastolic blood pressure, ocular pressure and visual field loss , the less the flow. Both the optic disk and

retinal circulation defects occur in untreated ocular hypertensive eyes. These observations indicate that circulatory defects in the optic disk and retina occur in ocular hypertension and open-angle glaucoma and increase 5 with the progression of the disease.

Thus it is evident that there is an unmet need for agents that have neuroprotective effects in the eye that can stop or retard the progressive damage that occurs to the nerves as a result of glaucoma 10 or other ocular afflictions.

### Summary of the Invention

A new method of protecting the optic nerve and retina of the 15 mammalian eye from damage by glaucoma and other noxious provocations has been discovered. This method comprises administering to the mammal either systemically or by intrabulbar injection an effective amount of one or more of certain aryl-imino-2-imidazolidines (as defined herein), salts thereof and mixtures thereof. This new method is particularly effective when 20 administered as a prophylactic treatment, i.e. before damage to the nerve takes place, or before long-term progression of the disease, such as glaucoma, has taken place.

25 Detailed Description of the Invention

The drawings will first be briefly described.

### Drawings

30 Figure 1 is a bar graph showing the percentage of cells killed by treatment with glutamate plotted by number of days since glutamate treatment. A control which was not treated with glutamate has been included to determine cell death which occurred without any such treatment. Also shown are measurements taken after treatment with both AGN191103 and glutamate, and treatment with MK-801 and 35 glutamate. MK-801 is a well known neuroprotective agent in the art. The numbers beneath the bars for glutamate; AGN191103 + glutamate; and MK-801 + glutamate show the concentrations of

-6-

glutamate and drug used in each case. At day 8, AGN 191103 and MK-801 show comparable effects in protecting cells from glutamate induced neurotoxicity. Experimental procedures followed in generating the data for this figure are detailed in Example 1.

5

Figure 2 shows plots of compound action potentials (CAP) measured for optic nerve fibers: in the left-hand frame, measured at 2 weeks post injury (i.e. after nerve crush) for optic nerve treated with AGN 191103 (the upper line) and for an untreated nerve used as a control (lower line); and in the right-hand frame a comparison CAP of non-injured optic nerve. The scales of the plots are given for each of the frames. The post-injury abscissa scale is 25 X the scale of the non-injured plot. (Units: millivolts and milliseconds). The value of the compound action potential is calculated as the integral of the area under each curve. The irregularity of the curve is a feature of the dispersion of the compound response; some nerve cells conduct more rapidly than others and so amplitude of the measured voltage varies with time.

10

15

20

25

30

Figure 3 is a bar graph showing the maximal CAP amplitude in microvolts ( $\mu$ V) for cells injured by a optic nerve crush in rats and treated with: 1) vehicle alone; 2) clonidine and 3) AGN191103. Each of the drugs was tested at four different concentrations (administered as a multiple of body weight for the test subject) and is represented by a bar on the chart. Clonidine was chosen as a benchmark  $\alpha_2$  agonist compound with very well defined pharmacology to compare against the test compound AGN 191103. While clonidine did show some neuroprotective activity over vehicle alone, it showed about half the maximal CAP response of AGN191013.

35

Figure 4 is a graphic plot of the Visual Evoked Potential Response and shows the electrical potential activity evoked at the surface of the visual cortex (comparable to an electroencephalogram) as a result of visual (light) stimulus. The test is performed in live rats and is a measure of the integrity of the whole visual system from the retina through the optic nerve into the lateral geniculate nucleus and ultimately to the visual cortex located in the back of the brain. The

left-hand frame shows the response without nerve crush injury and the right-hand frame shows the responses measured at 2 weeks post-injury for rats treated with AGN191103 above (labeled positive) and control rats below (labeled negative) prior to nerve crush. The scale 5 in  $\mu$ V vs. milliseconds for both plots is shown below the ordinate axis.

For a discussion and bibliography regarding the nerve crush model and its significance in evaluating nerve damage and recovery see:

10 "Functional Recovery and Morphological Changes after Injury to the Optic Nerve", Sabel, B.A. and Aschoff, A., Neuropsychobiology, 28, pp. 62-65 (1993).

Injury to the mammalian optic nerve, as in any other parts of the 15 mammalian central nervous system (CNS), leads to axonal degeneration followed by a loss of cell bodies, with failure of axonal regrowth from the surviving neurons. Initially, degeneration of the injured nerve is probably attributable to direct neuronal damage. However, the associated physiological and biochemical events 20 occurring in the nerve immediately after injury are probably responsible for the subsequent progressive degeneration, not only of the directly injured axons, but also of those that escaped the primary damage and largely determine the long-term functional outcome.

25 The immediate injury-induced response strongly influences the subsequent degenerative response. Treatment that reduces or attenuates the immediate response is therefore likely to achieve optimal prevention or delay of the secondary degenerative processes. For monitoring of the immediate response, it is obviously preferable 30 to employ a noninvasive technique. An adaptation of the nicotinamide adenine dinucleotide (NADH) monitoring technique to enable measurement of the earliest post-traumatic events has proved to be a valuable non-invasive approach. Use of the technique allows the immediate effect of the injury to be evaluated in real time 35 and on-line before and after a well-controlled crush injury inflicted on the adult rat optic nerve *in vivo*. In this experimental paradigm, measurement of the metabolic activity of the injured optic


nerves represent the activity of both injured axons and their associated non neuronal cells, and thus evaluate the potential ability to cope with injurious stresses. The model is also useful for monitoring the activity of various agents that may overcome or  
5 mitigate nerve cell damage or death from such stresses.

The earliest injury-induced response is a decrease in the energy state of the nerve, under conditions where ischemic events can be completely ruled out. The reduction in the energy state may be  
10 related to: 1) postinjury elevation in free fatty acid levels, which may interfere with mitochondrial function and result in uncoupling of electron transport; and 2) a marked rise in intracellular free  $\text{Ca}^{2+}$ . It is known that axonal injury is generally followed by an increase in extracellular potassium ions, which stimulate the uptake of  $\text{Ca}^{2+}$  via  
15 either voltage sensitive channels (L, T or N type) or receptor-operated  $\text{Ca}^{2+}$  channels. A marked rise in intracellular free  $\text{Ca}^{2+}$  can accelerate processes that are inimical to cell survival, including those involving  $\text{Ca}^{2+}$ -dependent enzymes, mainly lipases, proteases and endonucleases, that may cause mitochondrial damage and lead  
20 eventually to cell death. The cell, in order to overcome these events, needs more energy to actively restore ionic homeostasis. The combination of increased energy demands and decreased energy conservation resulting from mitochondrial dysfunction at the site of injury may be the major reason for the subsequent irreversible nerve  
25 damage and nerve degeneration following injury. Early measurement of metabolic activity could therefore indicate the fate of the axon, its associated glial cells and its non-neuronal cell bodies. It follows from the above that restoration of the mitochondrial activity may be critical in preventing the degenerative process  
30 occurring in the nerve after injury.

Since the injury inflicted on the nerve in the nerve crush model is a well-controlled, calibrated and reproducible lesion, it is possible to correlate early post-traumatic metabolic deficits and possible  
35 mitigation of these by drug or other treatments with long-term morphological and physiological effects.

From the foregoing figures and discussion it is apparent that neuroprotection is conferred on nerve cells to both glutamate-induced toxicity and physical insult in the nerve crush model.

5 It has now been discovered that neuroprotection is conferred upon ocular nerve cells by administration of a drug of formula I to the optic nerve and/or retina of a mammal within a period prior to or following an insult to ocular nerve cells but prior to cell death




10 formula I

wherein the 2-imidazolin-2-ylamino group may be in either the 5- or 6-position of the quinoxaline nucleus; x, y and z may be in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an  
15 optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy.


#### Definitions

The compound identified as AGN 191103 has the chemical structure  
20 as



shown. It is also known by the chemical nomenclature 6-methyl-(2-imidazolin-2-ylamino) quinoxaline.

The neuroprotective agent identified as MK-801 is also known by the name dizocilpine and has the following chemical structure:



It is additionally identified and described in the 11th edition of the Merck Index at monograph number 3392.

#### Human dosage and administration

The methods of this invention are useful in treating any mammal, including humans.

5 According to this invention, mammals are treated with pharmaceutically effective amount of a neuroprotective agent for a period of time and at a time such that noxious provocations to the optic nerve and retina do not kill or permanently damage the nerve cells. Protective agents may be administered orally or by any other  
10 appropriate means of delivery described below or known in the art.

In accordance with this invention, pharmaceutically effective amounts of a protective agent can be administered alone to treat nerve injury or to prevent nerve cell death. Alternatively a  
15 protective agent may be administered sequentially or concurrently with an antiglaucoma drug, e.g. a beta-blocker, an alpha<sub>2</sub> agonist, a muscarinic agent such as pilocarpine, a carbonic anhydrase inhibitor (CAI), or another drug useful in maintaining intraocular pressure (IOP) at normal levels or in lowering elevated IOP. The most  
20 effective mode of administration and dosage regimen of protective agent will depend on the type of disease to be treated, the severity and course of that disease, previous therapy, the patient's health status, and response to the drug and the judgment of the treating physician. Generally, the neuroprotective agent should be administered in a  
25 dose to achieve a serum or intravitreal concentration of 0.01 nM to 50 nM. Preferably the neuroprotective agent is administered prior to injury to the nerve, but can be administered after injury has occurred with lessened effect.  
30 Conventional modes of administration and standard dosage regimens of protective agents, e.g. MK-801, can be used. Optimal dosages for co-administration of a drug, e.g. an IOP-lowering drug, with a neuroprotective agent can be determined using methods known in the art. Dosages of neuroprotective agents may be adjusted  
35 to the individual patient based on the dosage of the drug with which the agent is co-administered and the response of the patient to the

treatment regimen. The protective agent may be administered to the patient at one time or over a series of treatments.

An agent that cannot pass the blood/brain barrier, e.g. MK-801, may

5 be administered locally, e.g. intravitrally by intrabulbar injection, or intrathecally. Agents which are capable of crossing the blood/brain barrier, e.g. AGN191103 can be administered systemically, e.g., orally, or intravenously, or by injection.

10 The composition used in these therapies may also be in a variety of forms. These include, for example, solid, semi-solid, and liquid dosage forms, such as tablets, pills, powders, liquid solution or suspension, liposomes, suppositories, injectable and infusible solutions. The compositions also preferably include conventional

15 pharmaceutically acceptable carriers which are known those of skill in the art.

The following non-limiting examples describe assays and measurements used in 1) determining protection of nerve cells from

20 glutamate induced toxicity and 2) methods of determining neural protection conferred by neuroprotective agents in a nerve crush model of mechanical injury.

Example 1:

25 Experimental procedure for measuring neural protection in a model of glutamate induced excitotoxic effects on nerve cells:

Low-density rat hippocampal neuronal cultures were prepared by the

30 procedure of Goslin and Banker. Coverslips were cleaned and sterilized in porcelain racks in such a way that they did not stick to one another (Cohen cover glass staining racks, Thomas Scientific). Coverslips (13 mm) were placed in staining racks, rinsed in distilled water (four rinses, 1 min. each) to remove dust and transferred to

35 concentrated HNO<sub>3</sub> for 36 hours. Coverslips were rinsed in distilled water (four changes over 3 hours) and sterilized with dry heat (overnight at 225° C). The coverslips were transferred to 24-well dishes, one coverslip per well. To support the coverslips above the

-12-

glia during coculturing, paraffin dots were placed on dishes, and UV irradiation (30 min.) was applied before the coverslips were introduced. One mg/mL of poly-L-lysine hydrobromide (PLL) (Sigma) (MW 30,000-70,000) was dissolved in borate buffer (0.1 M, pH 5 8.5), filtered, sterilized and used to cover each coverslip overnight.

The PLL was removed, coverslips were rinsed in distilled water (two washes, 2 hrs. each), plating medium [Eagle's MEM with Earle's salts containing extra glucose (600 mg/L) and 10% horse serum] was added and the dishes were stored in an incubator. Astroglial cultures were prepared from the brains of neonatal rats by a method similar to that described by Levinson and Mc Carthy, except that they were plated at a lower density so that they contained predominantly type 1 astroglia. 10<sup>5</sup> cells were plated in each well. Glial cultures were fed with plating medium twice a week and were used after reaching confluence, about 10 2 weeks after plating . One day before use, the plating medium was removed, neuronal maintenance medium (MEM containing N2 supplements) was added, and incubation continued. 3 X 10<sup>4</sup> of viable rat hippocampal nerves (E18 embryos) were plated on the PLL-treated coverslips kept in plating medium. After 3-4 hrs, when most of the 15 neurons were attached, the coverslips were transferred to the dishes containing the glial cell in maintenance medium in such a way that the neuronal side was facing the glia, which support neuronal survival and development. To reduce glial proliferation, cytosine arabinoside (1-b-D-arabinofuranosylcytosine)(Calbiochem)(5 X 10<sup>-6</sup> M final concentration) was added to the cultures 2 days after plating. At 20 day 6 in culture, cells were treated with 1mM glutamate or with glutamate together with either AGN-191103 - 0.1 nM (MW = 200) or MK-801 - 10 nM (2-3 coverslips were used to each treatment).

25 After 24 hrs. of incubation, cells were stained with trypan blue. Live and dead neurons were counted from randomly selected culture fields (5 fields from each coverslip) . Percentage of dead cells was calculated.

Example 2:

5      Procedure for nerve crush injury and measurements of compound action potentials (CAP) subsequent to injury.

Part A.

Metabolic Measurements

10     Animal utilization was according to the ARVO Resolution on the use of animals in research. Male Sprague-Dawley (SPD) rats weighing 300-400 g were anesthetized with sodium pentobarbitone (intraperitoneally, 35 mg/kg). A cannula was introduced into the

15     trachea for artificial ventilation when required. With the animal's head held in place by a head holder, a lateral canthotomy was performed under a binocular operating microscope and the conjunctiva was incised lateral to the cornea. After separation of the retractor bulbi muscles, the optic nerve was identified and a length of

20     30 3.5 mm was exposed near the eyeball by blunt dissection. The dura was left intact and care was taken not to injure the nerve. The first part of a light guide holder (see below) was inserted under the optic nerve and the nerve was gently eased into the light guide canal. The second part was then fixed in place in such a way that the light guide

25     was located on the surface of the optic nerve 1 mm from the site at which the injury was to be administered.

Surface fluorometry-reflectometry

30     Monitoring of the intramitochondrial NADH redox state was based on fluorescence of NADH at 366 nm, resulting in the emission of blue light with a peak intensity at 450 nm, which is unlike its oxidized form, NAD+, which lacks this fluorescence. The source of the 366 nm excitation is a 100-W air-cooled mercury lamp equipped

35     with a strong 366-nm filter (Corning 5860 (7-37) plus 9782 (4-96)). A flexible Y-shaped bundle of optic fibers (light guide) is used to transmit the light to and from the optic nerve, thus making *in vivo* measurements technically feasible. Excitation light is transmitted through the bundle of excitation fibers to the nerve. The light emitted from the nerve, after being transmitted through a second

-14-

bundle of fibers, is split in a ration of 90:10 for measurement of the fluorescent light (90%) at 450 nm and the reflected light (10%) at 366 nm by two photomultipliers connected to a one-channel direct current fluorometer-reflectometer. In order to minimize variations  
5 among animals, standard signal calibration procedures were applied at the start of the recordings. Changes in the fluorescence and reflectance signals during the experiment are calculated relative to the calibrated signals. This type of calibration, although not absolute, has nevertheless been found to yield reliable and reproducible results  
10 from various animals and among different laboratories.

Changes in reflected light were correlated with changes in tissue absorption caused by hemodynamic effects and movements of the optic nerve secondary to alteration in arterial blood pressure and  
15 nerve volume. The fluorescence measurements are found to be adequately corrected for NADH redox state measurements by subtraction of the reflected light (366 nm) from the fluorescent light (1:1 ratio) to obtain the corrected fluorescence signal.

20 Metabolic Measurements

Animals which were still anesthetized were allowed to recover for 30 min. from the surgical procedures described above and were then exposed to anoxic and hyperoxic conditions. An anoxic state was  
25 achieved by having the rat breathe in an atmosphere of 100% nitrogen for 2 min., after which it was returned to air. Whenever animals did not return spontaneously to normal breathing, they were ventilated by blowing twice into the trachea. A hyperoxic state was induced by having the animal breathe 100% oxygen for 6-10 min.  
30 In order to evaluate the metabolic activity of the optic nerve, the relative changes in reflected and fluorescent light intensities in response to anoxia and to hyperoxia were measured before and after crush injury.

-15-

### Experimental Protocol For Metabolic Measurements

Using calibrated cross-action forceps, a well-calibrated moderate crush injury was inflicted to the nerve between the eye and the light guide holder at a pressure corresponding to 120 g for 30 sec.

#### Part B.

##### Physiological Measurements

10 Experimental setup for recording compound action potential (CAP): Prior to removal of optic nerves for electrophysiological measurement, the rats were deeply anesthetized with 70 mg/kg pentobarbitone. The skin was removed from the skull and the optic nerves were detached from the eyeballs. Subtotal decapitation was performed and the skull was opened with a rongeur. The cerebrum was displaced laterally, exposing the intracranial portion of the optic nerve. Dissection at the level of the chiasm enabled removal of the whole length of the nerve, which was transferred to vials containing

15 fresh, cold Krebs solution, consisting of: NaCl (125 mM), KCl (5 mM), KH<sub>2</sub>PO<sub>4</sub> (1.2mM), NaHCO<sub>3</sub> (26 mM), MgSO<sub>4</sub> (0.6 mM), CaCl<sub>2</sub> (24 mM), D-glucose (11 mM), aerated with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. The nerves were kept in this solution, in which electrical activity remained stable for at least 3-4 h. After 1 h of recovery, nerves were

20 25 immersed in Krebs solution at 37° C. Electrophysiological recording were obtained from the nerve distal to the crush lesion, since the nerves were too small to allow measurement on both sides of the crush. The nerve ends were then connected to two suction Ag-AgCl electrodes immersed in the bathing solution. The stimulating pulse

30 35 was applied through the electrode at the proximal end and the action potential was recorded by the distal electrode. A Grass SD9 stimulator was used for electrical stimulation (2 V, 50 µs). The signal was transmitted to a Medelec PA63 preamplifier and thence to a Medelec MS7 electromyograph and AA7T amplifier. The solution, stimulator and amplifier had a common ground. The maximum amplitude of eight averaged CAPs was recorded and photographed with a Polaroid camera. The left nerves (uninjured) were used to measure the reference values of normal nerves and to calibrate the crush forceps.

Recording of Visual Evoked Potential (VEP) Response

Injured drug-treated rats were examined in 2 weeks after the injury  
5 for assessment of their functional recovery. In this set of experiments, the pattern of field potentials in response to light stimulation was recorded from the primary visual cortex. The potential evoked by the light originates in the retina and is propagated along the surviving axons to reach their final target, the  
10 visual cortex. Only those axons that survived the primary and secondary degenerative processes are capable of conducting an action potential. A comparative analysis of the pattern of field potentials in treated and untreated animals will reveal the effect of the treatment on axonal survival.

15 Anesthetized rats (Rumpon, Ketalar) were placed in a small animal stereotaxic instrument. After exposure of the skull, two holes were drilled with a cylindrical drill bit, with the dura kept intact to minimize cortical damage. One hole, drilled above the nasal bone,  
20 was used as a reference point. The second hole was in the area OC1 with the coordinates Bregma # 8 mm, lateral # 3 mm. A gold contact pin connected to a screw was used as the electrode, which was screwed into the holes and glued by acrylic cement to the skull. The field potential was evoked by stroboscopic stimulation, with an  
25 average of 90 sweeps per minute. The flash-evoked potential was analyzed by the use of the Lab View data acquisition and management system. The field potentials were digitized and stored for off-line analysis.

30 Part C.

Measurement of effects of drug tests for neural protective properties

The first set of experiments involved metabolic measurements. Each  
35 drug was injected intraperitoneally at several different concentrations. Each drug was tested in a group of 8 animals, together with 8 controls (injured animals treated with the buffer vehicle). In each case, metabolic measurements were obtained on-line before

-17-

injury, 0.5 h after injury and every hour for 4-6 h thereafter. The data obtained were analyzed by ANOVA.

Measurement of long term effects. Physiological Activities.

5      CAPS

Immediately after injury, the drug to be tested was injected into 10 animals, and 10 control animal's were injected with vehicle. Two weeks later the CAPs of each nerve were recorded in vitro, using suction electrodes. The contralateral side was used as an internal control. The results indicated whether the examined drug had any potential effects on the rescue of spared axons and / or slowing of degeneration. Positive results led to efforts at determining the optimal dosage for each promising drug.

VEP response

Electrodes were implanted in the cortex of naive SPD rats in two age- and sex-matched groups. Immediately after implantation, the VEP response was recorded from the left side while a light was flashed into the right eye, with the left eye covered. A well-controlled crush injury was then inflicted on the optic nerve and the drug was immediately administered at the previously determined optimal dosage. Control animals were handled in the same way except vehicle was administered rather than drug. The VEP response for each animal was recorded 1 day, 1 week, 2 weeks and 4 weeks after operation.


30      While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereby and should only be construed by interpretation of the scope of the appended claims.

CLAIMS

What is claimed is:

5

1) A method of protecting the retinal or optic nerve cells in a mammal suffering a noxious action or at risk of experiencing a noxious action on said nerve cells comprising administering to said mammal an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death



formula I

wherein the 2-imidazolin-2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy, or pharmaceutically acceptable salts thereof and mixtures thereof.

15

2) The method of claim 1 wherein the noxious action is the elevated intraocular pressure of glaucoma.

3) The method of claim 1 wherein the noxious action is ischemia associated with glaucoma.

4) The method of claim 1 wherein the noxious action is diabetic retinopathy.

20  
25  
30 5) The method of claim 1 wherein the noxious action is non-glaucomatous ischemia.

-19-

6) The method of claim 1 wherein the noxious action is microangiopathic in nature and is a symptom of the disease chosen from the group consisting of polyarteritis nodosa, giant cell arteritis, aortitis syndrome and systemic lupus erythematosus.

5

7) The method of claim 1 wherein oral administration is used to supply the compound to the mammal systemically.

8) The method of claim 7 wherein the amount of the compound  
10 administered is from 5 - 15 mg/kg.

9) The method of claim 1 wherein intrabulbar injection in the eye is used to supply the compound to the mammal.

15 10) The method of claim 1 wherein parenteral administration is used to supply the compound to the mammal systemically.


11) The method of claim 1 wherein intramuscular injection is used to supply the compound to the mammal systemically.

20

12) The method of claim 1 wherein the compound of formula I has the 2- imidazolin-2-ylamino group at the 6-position of the quinoxaline ring, y and z are both hydrogen and located at the 7- and 8-positions and x is at the 5-position of the quinoxaline ring.


25

13) The method of claim 1 wherein the compound of formula I is




-20-

14) The method of claim 1 wherein the compound of formula I is




15) The method of claim 1 wherein the compound of formula I is




5 wherein x is as defined in claim 1 and the noxious action is elevated intraocular pressure.

16) The method of claim 1 wherein the compound of formula I is



10 wherein x is as defined in claim 1 and the noxious action is ischemia associated with glaucoma.


17) The method of claim 1 wherein the compound of formula I is



15 wherein x is as defined in claim 1 and the noxious action is diabetic retinopathy.

-21-


18) The method of claim 1 wherein the compound of formula I is



wherein x is as defined in claim 1 and the noxious action is non-glaucomatous ischemia.

5

19) The method of claim 1 wherein the compound of formula I is



wherein x is as defined in claim 1 and the noxious action is microangiopathic in nature and is chosen from the group consisting  
10 of polyarteritis nodosa, giant cell arteritis, aortitis syndrome and systemic lupus erythematosus.

FIG. 1.

112





FIG. 2.

FIG. 3.

2/2

FIG. 4.

**A. CLASSIFICATION OF SUBJECT MATTER**  
**IPC 6 A61K31/495**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
**IPC 6 A61K**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 426 390 (ALLERGAN, INC.) 8 May 1991 see the whole document ---	1-3,7-16
X	US,A,5 215 991 (BURKE) 1 June 1993 see column 1, line 16 - line 21 ---	1-3,7-16
X,P	WO,A,96 13267 (ALLERGAN, INC.) 9 May 1996 see page 1, line 18 - line 26 ---	1-3,7-16
X	US,A,5 180 721 (BURKE) 19 January 1993 see column 1, line 18 - line 24 ---	1-3,7-16
X	EP,A,0 422 878 (ALLERGAN, INC.) 17 April 1991 see page 4, line 50 - page 5, line 49 ---	1-3,7-16
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

8 October 1996

Date of mailing of the international search report

22.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Theuns, H

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	<p>INVESTIGATIVE OPHTHALMOLOGY &amp; VISUAL SCIENCE, vol. 37, no. 3, 15 February 1996, page s114 XP002015357 E. YOLES ET AL.: "INJURY-INDUCED SECONDARY DEGENERATION OF RAT OPTICAL NERVE CAN BE ATTENUATED BY ALPHA<sub>2</sub>-ADRENOCEPTOR AGONISTS AGN 191103 AND BRIMONIDINE" see abstract</p> <p>---</p>	1-19
X	<p>DRUGS AGING, vol. 5, no. 3, September 1994, pages 156-170, XP000578323 J.B.SERLE: "Pharmacological Advances in the Treatment of Glaucoma" see page 163 - page 164</p> <p>---</p>	1-19
X	<p>ARCH.OPHTHALMOL., vol. 111, no. 10, October 1993, pages 1387-1390, XP000578325 R.DAVID ET AL.: "Brimonidine in the Prevention of Intraocular Pressure Elevation Following Argon Laser Trabeculoplasty" see the whole document</p> <p>---</p>	1-19
X	<p>OPHTHALMOLOGY, vol. 100, no. 7, July 1993, pages 1083-1088, XP000578322 H.S. BARNEBEY ET AL.: "The Efficacy of Brimonidine in Decreasing Elevations in Intraocular Pressure after Laser Trabeculoplasty" see the whole document</p> <p>-----</p>	1-19

## INTERNATIONAL SEARCH REPORT

PCT/US 96/ 10468

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1 - 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0426390	08-05-91	US-A-	5021416	04-06-91
		AT-T-	122233	15-05-95
		AU-B-	627626	27-08-92
		AU-A-	6396690	09-05-91
		CA-A-	2025189	01-05-91
		DE-D-	69019297	14-06-95
		DE-T-	69019297	12-10-95
		ES-T-	2074138	01-09-95
		JP-A-	3153626	01-07-91
		SU-A-	1829937	23-07-93
-----	-----	-----	-----	-----
US-A-5215991	01-06-93	NONE		
-----	-----	-----	-----	-----
WO-A-9613267	09-05-96	NONE		
-----	-----	-----	-----	-----
US-A-5180721	19-01-93	US-A-	5021410	04-06-91
		AU-A-	2176492	08-01-93
		WO-A-	9221349	10-12-92
		US-A-	5281591	25-01-94
		CA-A-	2014036	22-11-90
		EP-A-	0399791	28-11-90
		JP-A-	3020219	29-01-91
-----	-----	-----	-----	-----
EP-A-0422878	17-04-91	US-A-	5077292	31-12-91
		AU-B-	628666	17-09-92
		AU-A-	6390090	18-04-91
		CA-A-	2025212	13-04-91
		DE-D-	69008472	01-06-94
		DE-T-	69008472	15-09-94
		ES-T-	2063289	01-01-95
		JP-A-	3145490	20-06-91
		US-A-	5326763	05-07-94
		WO-A-	9213855	20-08-92
		US-A-	5373010	13-12-94
		US-A-	5418234	23-05-95
		US-A-	5112822	12-05-92
		US-A-	5204347	20-04-93
		US-A-	5231096	27-07-93
		US-A-	5198442	30-03-93
		US-A-	5300504	05-04-94